Drug Design, Development and Therapy
2026
Jie Yang, Qiqi Yan, Ting Zhang et al.
Esketamine is increasingly being applied for preventing postpartum depression (PPD). However, clinical protocols for this application are inconsistent, particularly concerning the route of administration. The aim was to determine whether esketamine bolus administration differed from continuous infusion in terms of preventing PPD. A total of 503 subjects without prenatal depression undergoing...
Drug Design, Development and Therapy
2026
Fan Bu, Lan Qin, Zhengchi Lou et al.
Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability...
General Hospital Psychiatry
2026
David T. Kryszajtys, Carol Strike, Brian Rush et al.
1 citation
Some individuals interpret persistent depression and anxiety, alongside the exhaustion of standard treatment options, as leading to a desperate need for relief. While desperation may shape how people assess treatment options, its role in psychedelic self-treatment and its relevance for emerging clinical models of psychedelic treatment remain underexplored. We collected discussion threads from...
Journal of Neuroscience Research
2026
Stephanie N Njau, Artemis Zavaliangos-Petropulu, Shantanu Joshi et al.
Ketamine has emerged as a highly effective intervention for treatment-resistant depression (TRD). Though it acts as a non-competitive antagonist of excitatory N-methyl-D-aspartate receptors (NMDAR), widely expressed in the brain, including on inhibitory γ-aminobutyric acid (GABA)-ergic cells, the mechanisms of its antidepressant action are less clear. To investigate the links between glutamate...
General Hospital Psychiatry
2026
Rebeca Cohen, João Bastos, Catarina Cunha et al.
1 citation
Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...
Frontiers in Psychiatry
2026
Ahmad H Almadani, Ayedh H Alghamdi, Gosay M Almazyad et al.
Esketamine is an innovative treatment for individuals with treatment-resistant depression (TRD). However, its adoption could depend on the perceptions and motivations of prescribing psychiatrists, among other factors. This study aims to explore the attitudes of psychiatrists (of all levels, including those in training) across Saudi Arabia toward the use of esketamine for TRD and investigate the...
American Journal of Translational Research
2026
Ran Jing, Yuanyan Tu
To investigate the effects of single low-dose esketamine combined with patient-controlled intravenous analgesia (PCIA) on early postpartum depression symptoms and recovery quality in women undergoing cesarean section. This prospective, randomized, controlled study enrolled 136 women scheduled for elective cesarean section, who were randomly assigned in a 1:1 ratio to the study group (esketamine...
Frontiers in Psychiatry
2026
Hang Yu, Yuqiong Zhu, Jie Wang et al.
Esketamine has a significant and rapid antidepressant effect. Although studies have shown that Neuregulin 1 (NRG1) and it's signaling pathway are associated with depression, the possible regulatory relationship of esketamine on the NRG1-ErbB4 pathway is not yet clear. To induce depressive-like behavior in mice, a Chronic Social Defeat Stress (CSDS) model was established. Behavioral indicators...
Therapeutic Advances in Psychopharmacology
2026
Alessandro Cuomo, Roger S McIntyre, Despoina Koukouna et al.
1 citation
Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited. To describe long-term dosing patterns and clinical outcomes associated with intranasal esketamine in routine clinical practice. Single-center observational cohort study with descriptive analyses. We analyzed 45 patients with TRD treated with intranasal...
Frontiers in Pharmacology
2026
Michaela Krivosova, Matteo Marcatili, Gessica Guerrera et al.
Esketamine, the S-enantiomer of ketamine, is a rapid-acting antidepressant approved for treatment-resistant depression (TRD) when used in combination with an oral antidepressant. Identifying reliable clinical or genetic predictors of treatment response remains a critical unmet need. This study aimed to evaluate the impact of selected clinical and genetic variables on esketamine response in a...